Prevention of Anthracycline Cardiotoxicity by Iron Chelation

Acta Haematologica

Volumn 95, Issue 1, 1996, Pages 87-92

  Hershko, Chaim ^a   Pinson, Arie ^b   Link, Gabriela ^c  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b Laboratory of Myocardial Research   (Israel)

^c HEBREW UNIVERSITY   (Israel)

Author keywords

Antracyclines; Cardiotoxicity; Deferoxamine; Doxorubicin; Free radicals; Iron chelators; Iron overload; Toxicology

Indexed keywords

3 HYDROXY 4 PYRIDONE DERIVATIVE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CARDIOLIPIN; DEFEROXAMINE; DOXORUBICIN; EDETIC ACID; FREE RADICAL; IRON; PHOSPHOLIPID; POLYUNSATURATED FATTY ACID; RAZOXANE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOTOXICITY; CELL ORGANELLE; ENZYME INACTIVATION; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; IRON CHELATION; LIPID PEROXIDATION; LYSOSOME; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL RESPIRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SARCOLEMMA; SARCOPLASMIC RETICULUM;

ANTIBIOTICS, ANTINEOPLASTIC; FREE RADICALS; HEART DISEASES; HUMANS; IRON; IRON CHELATING AGENTS;

EID: 0030058377     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000203954     Document Type: Article

References (68)

1. Young RC, Ozols RF, Myers CE: The anthra-cyeline antincoplastic drugs. N Engl J Med 1981;305:139-153.
2. Rinehart JJ, Lewis RP, Balcerzak SP: Adria-mycin toxicity in man. Ann Intern Med 1974; 91:475-478.
3. Gottdiener JS, Mathisen DJ, Borer JS, Bonow RO, Myers CE, Barr LH, Schwartz DE, Bacha-rach SL, Green MW, Rosenberg SA: Doxorubicin cardiotoxicity: Assessment of the left ventricular dysfunction by radionuclide cineangiography. Ann Intern Med 1981;94:430-435.
4. Lee BH, Goodenday LS, Muswick GJ, Yasnoff WA, Leighton RF, Skeel RT: Alterations in left ventricular diastolic function with doxorubicin therapy. J Am Coll Cardiol 1987;9:184-188.
5. Singal PK, Deally CMR, Weinberg LE: Subel-lular effects of adriamycin in the heart: A concise review. J Mol Cell Cardiol 1987;19:817— 828.
6. Hagane K, Akera T, Bcrliun JR: Doxorubicin: Mechanism of cardiodepressant actions in guinea pigs. J Pharmacol Exp Ther 1988;246: 655-661.
7. Olson RD, Mushlin PS: Doxorubicin cardiotoxicity: Analysis of prevailing hypotheses. FASEBJ 1990;4:3076-3086.
8. Tritton TR, Yee G: The anticancer agent adriamycin can be actively cytotoxic without entering cells. Science 1982;217:248-250.
9. Solie TN, Yuncker C: Adriamycin induced changes in translocation of sodium ions in transporting epithelial cells. Life Sci 1978;221: 1907-1920.
10. Murphree SA, Cunningham LS, Hwang KM, Sartorelli AC: Effects of adriamycin on surface properties of sarcoma 180 ascites cells. Biochem Pharmacol 1976;25:1227-1231.
11. Caroni P, Villani F, Carafole E: The cardio-toxic antibiotic doxorubicin inhibits the Na/Ca exchange of dog heart sarcolemmal vesicles. FEBSLett 1981;130:184-186.
12. Harada H, Cusack BJ, Olson RD, Stroo W, Azuma J, Hamaguchi T, Schaffer SW: Taurine deficiency and doxorubicin: Interaction with the cardiac sarcolemmal calcium pump. Biochem Pharmacol 1990;39:745-751.
13. Singal PK: Ultrastructural evidence for increased sensitivity of the hypertrophied heart to adriamcycin. Perspect Cardiovasc Res 1983; 7:197-209.
14. Singal PK, Segstro RJ, Singh RP, Kutryk MJ: Changes in lysosomal morphology and enzyme activities during the development of adriamy-cin-induced cardiomyopathy. Can J Cardiol 1985;1:139-147.
15. Younes M, Albrecht M, Siggers CP: Lipid peroxidation and lysosomal enzyme release induced by vanadate in vitro. Res Commun Chcm Pathol Pharmacol 1984;43:87-97.
16. Abramson JJ, Salama G: Sulfhydryl oxidation and calcium release from sarcoplasmic reticulum. Mol Cell Biochem 1988;82:81-84.
17. Kim DH, Landry AB, Lee YS, Katz AM: Doxorubicin-induced calcium release from sarcoplasmic reticulum vesicles. Mol Cell Cardiol 1989;21:433-436.
18. Zorzato F, Salviati G, Facchinetti T, Volpe P: Doxorubicin induces calcium release from terminal cistemae of skeletal muscle. J Biol Chem 1985;260:7349-7355.
19. Jennings RB, Ganóte CE: Mitochondrial structure and function in acute myocardial ischemia. Circ Res 1976;38 (suppl 1): 180-191.
20. 2* binding and lipid peroxidation but depresses myocardial function. Am J Physiol 1986;250:419-425.
21. Lowe MC, Smallwood JI: Adriamycin and dau-nomycin dose-dependent effects upon contraction of isolated rat myocytes. Cancer Chemo-ther Pharmacol 1980;5:61-65.
22. Seyardarian MW, Artza L: Modification by adenosine of the effect of adriamycin on myocardial cells in culture. Cancer Res 1979;39: 2940-2944.
23. Dhalla NS, Pierce GNB, Panaglia V, Singal PK, Beamish RE: Calcium movements in relation to heart function. Basic Res Cardiol 1982; 77:117-139.
24. Goormaghtigh E, Ruysschaert JM: Anthracy-clinc glycoside-membrane interactions. Bio-chim Biophys Acta 1984;779:271-288.
25. Mailler K, Petering DH: Inhibition of the oxidative phosphorylation in tumor cells and mitochondria by daunomycin and adriamycin. Biochem Pharmacol 1976;25:2085-2089.
26. Parkes JG, Thompson W: The composition of phospolipids in outer and inner mitochondrial membranes from guinea pig liver. Biochim Biophys Acta 1970;196:162-169.
27. Fry M, Green DE: Cardiolipin requirement by cytochrome oxidase and the catalytic role of phospholipid. Biochem Biophys Res Commun 1980;93:1238-1246.
28. Goormaghtigh E, Brasseur R, Ruysschaert JM: Adriamycin inactivates cytochrome C oxidase by exclusion of the enzyme from its cardiolipin essential environment. Biochem Biophys Res Commun 1982;104:314-320.
29. Batelli D, Beilei M, Arrigoni-Martelli E, Muc-scatello U, Bobyleva V: Interaction of carnitine with mitochondrial cardiolipin. Biochim Biophys Acta 1992; 1117:33-36.
30. Iwamoto Y, Hansen IL, Porter TH: Inhibition of cocnzyme Qio-cnzymes, succinoxidase and NADH-oxidase by adriamycin and other qui-nones having antitumor activity. Biochem Biophys Res Commun 1974;58:633-638.
31. Kishi T, Watanabe T, Folkers K: Bioenergetics in clinical medicine: Prevention by forms of coenzyme Q of the inhibition by adriamycin of coenzyme Qio-enzymes in mitochondria of the myocardium. Proc Natl Acad Sci USA 1976; 73:4653-4656.
32. Painter RB: Inhibition of DNA replication initiation by 4-nitroquinoIine 1-oxide adriamycin and ethyleneimine. Cancer Res 1978;38:4445— 4449.
33. Ito H, Miller SC, Billingham ME, Akimoto H, Torti SV, Wade R, Gahlmann R, Lyons G: Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc Natl Acad Sci USA 1990;87: 4275-4279.
34. Powis G: Free radical formation by antitumor quinones. Free Radic Biol Med 189,6:63-101.
35. Odom LA, Hatwig CA, Stanley JS, Benson AM: Biochemical determinants of adriamycin toxicity in mouse liver, heart and intestine. Biochem Pharmacol 1992;43:831-836.
36. Unverferth DV, Leier CV, Balcerzak SP, Hamlin RL: Usefulness of a free radical scavenger in preventing doxorubicin-induced heart failure in dogs. Am J Cardiol 1985;56:157-161.
37. Piccinini F, Monti E, Paracchini L, Perletti G: Are oxygen radicals responsible for the acute cardiotoxicity of doxorubicin? in Emerit (ed): Antioxidants in Therapy and Preventive Medicine New York, Plenum, 1990, pp 349-352.
38. Koukay N, Mouhieddine S, Richard MJ, Ar-naud J, de Leiris J, Favier A: Influence of selenium on lipid peroxidation and cardiac functions in chronically adriamycin-trcaded rats. Adv Exp Med Biol 1990;264:353-359.
39. Singh Y, Ulrich L, Katz D, Bowen P, Krishna G: Structural requirements for anthracycline-induced cardiotoxicity and antitumor effects. Toxicol Appl Pharmcol 1989;100:9-23.
40. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC: Adriamycin: The role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977; 197:165— 167.
41. Hrushesky WJM, Olshefski R, Wood P, Mesh-nick S, Eaton JW: Modifying intracellular redox balance: An approach to improve therapeutic index. Lancet 1985;i:565—567.
42. Dickinson AC, DeJordy JD, Teres D: Absence of generation of oxygen-containing free radicals with 4'-deoxydoxorubicin iron-cardiotoxic drug. Proc Am Assoc Cancer Res 1984,25:296-301.
43. Myers CE: Role ofiron in anthracycline action; in Hacker MP, Lazo JS, Tritton TR (eds): Organ Directed Toxicities of Anticancer Drugs. Boston, Martinus Nijhoff, 1988, p 17.
44. Gutteridge JMC: Adriamycin-iron catalysed phospholipid peroxidation: A reaction not involving adriamycin or hydroxyl radicals. Biochem Pharmacol 1983;32:1945-1949.
45. Minotti G: NADPH- and adriamycin-depcn-dent microsomal release of iron and lipid peroxidation. Arch Biochem Biophys 1990;277: 268-276.
46. Gutteridge JMC, Richmond R, Halliwell B: Inhibition of the iron-catalysed formation of hydroxyl radicals from superoxide and of lipid peroxidation by desferrioxamine. Biochem J 1979;184:469-472.
47. Halliwell B: Protection against tissue damage in vivo by desferrioxamine: What is its mechanism of action? Free Radic Biol Med 1989;7: 645-651.
48. Spreyer JL, Green MD, Kramer E, Rey M, Muggia F: Protective effect of the bispiperazi-nedione ICRF-187 against doxorubicin-in-duced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988:319: 745-752.
49. Creighton AM, Heilman K, Whitecross S: Antitumour activity in a series of bisdiketopipera-zines. Nature 1969,222:384-385.
50. Herman EH, Ferrans VJ: Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (±)-bis (3,5-dioxopiperazinyI-l-yl) propane (ICRF-187). Cancer Res 1981;41: 3436-3440.
51. Yeung TK, Jaenke RS, Wilding D, Creighton AM, Hopewell JW: The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat. Cancer Chemother Pharmacol 1992;30:58-64.
52. Woodman RJ, Cysyk RL, Kline I, Kidd TR: Enhancement of the effectiveness of daunoru-bicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943). Cancer Chemother Rep 1975;59:689-695.
53. Rajagopalan S, Politi PM, Sinha BK: Adriamy-cin-induced free radical formation in the perfused rat heart: Implications for cardiotoxicity. Cancer Res 1988;48:4766-4769.
54. Voest EE: Iron Chelation, Oxygen Radicals, and Anthracyclines in the Treatment of Cancer. Utrecht, Kwiek 1993.
55. al-Harbi MM, al-Gharably NM, al-Shabanah OA, al-Bekairi AM, Osman AM, Tawfik HN: Prevention of doxorubicin-induced myocardial and haematological toxicities in rats by the iron chelator desferrioxamine. Cancer Chemother Pharmacol 1992;31:200-204.
56. Moreb J, Hershko C, Hasin Y: Effects of acute iron loading on contractility and spontaneous beating rate of cultured rat myocardial cells. Basic Res Cardiol 1988;83:360-368.
57. Link G, Pinson A, Hershko C: Heart cells in culture: A model of myocardial iron overload and chelation. J Lab Clin Med 1985; 106:147— 153.
58. Link G, Pinson A, Kahane I, Hershko C: Iron loading modifies the fatty acid composition of cultured rat myocardial cells and liposomal vesicles: Effect of ascorbate and a-tocopherol on myocardial lipid peroxidation. J Lab Clin Med 1989;114:243-249.
59. Hershko C, Link G, Pinson A: Modification of iron uptake and lipid peroxidation by hypoxia, ascorbic acid, and a-tocopherol in iron-loaded rat myocardial cell cultures. J Lab Clin Med 1987;110:355-361.
60. Link G, Athias P, Grynberg A, Pinson A, Hershko C: Effect of iron loading on transmembrane potential, contraction and automa-ticity of rat ventricular muscle cells in culture. J Lab Clin Med 1989;113:103-111.
61. Hershko C, Link G, Pinson A, Peter HH, Dobbin P, Hider RC: Iron mobilization from myocardial cells by 3-hydroxypyridin-4-one chelators: Studies in rat heart cells in culture. Blood 1991;77:2049-2053.
62. Link G, Athias P, Grynberg A, Hershko C, Pinson A: Iron loading modifies (5-adrenergic responsiveness of cultured ventricular myocytes). Cardioscience 1991;2:27-30.
63. Link G, Pinson A, Hershko C: Iron-loading of cultured cardiac myocytes modifies sarcolemmal structure and increases lysosomal fragility. J Lab Clin Med 1993;121:127-134.
64. Hershko C, Link G, Tzahor M, Pinson A: Anthracycline toxicity is potentiated by iron and inhibited by deferoxamine: Studies in rat heart cells in culture. J Lab Clin Med 1993; 122: 245-251.
65. Link G, Pinson A, Hershko C: Ability of the orally effective iron chelators dimethyl- and diethyl-hydroxypyrid-4-one and of deferoxamine to restore sarcolemmal thiolic enzyme activity in iron-loaded heart cells. Blood 1994:83: 2692-2697.
66. Ledcrman HM, Cohen A, Lee JW, Freedman MH. Gelfand EW: Deferoxamine: A reversible S-phase inhibitor of human lymphocyte proliferation. Blood 1984,66:748-753.
67. Hoflbrand AV, Ganeshaguru K, Hooton JWL, Tattersall MHN: Effect of iron deficiency and desferrioxamine on DNA synthesis in human cells. Br J Haematol 1976;33:517-526.
68. Doroshow JH: Prevention of doxorubicin-in-duccd killing of MCF-7 human breast cancer cells by oxygen radical scavengers and iron chelating agents. Biochem Biophys Res Commun 1986;135:330-335.